Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2015

Open Access 01-12-2015 | Research article

Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye

Authors: Kaori Ueda, Wataru Matsumiya, Keiko Otsuka, Yoshifumi Maeda, Takayuki Nagai, Makoto Nakamura

Published in: BMC Ophthalmology | Issue 1/2015

Login to get access

Abstract

Background

Rebamipide with mucin secretagogue activity was recently approved for the treatment of dry eye. The efficacy and safety in the treatment of rebamipide were shown in two pivotal clinical trials. It was the aim of this study to evaluate the effect of 2 % rebamipide ophthalmic suspension in patients with dry eye and analyze relevant factors for favorable effects of rebamipide in clinical practice.

Methods

This was a retrospective cohort study of 48 eyes from 24 patients with dry eye treated with 2 % rebamipide ophthalmic suspension. Dry eye-related symptom score, tear film break-up time (TBUT), fluorescein ocular surface staining score (FOS) and the Schirmer test were used to collect the data from patients at baseline, and at 2, 4, 8, and 12 week visits. To determine the relevant factors, multiple regression analyses were then performed.

Results

Mean dry eye-related symptom score showed a significant improvement from the baseline (14.5 points) at 2, 4, 8 and 12 weeks (9.80, 7.04, 7.04 and 7.83 points, corrected P value <0.001, respectively). Median FOS showed a significant improvement from the baseline (3.0 points) at 2, 4, 8 and 12 weeks (2.0, 2.0, 1.0 and 1.0 points, corrected P value <0.001, respectively). TBUT and Schirmer test values were not significantly improved after the treatment. For ocular symptoms, three parameters (foreign body sensation, dry eye sensation and ocular discomfort) showed significant improvements at all visits. The multiple regression analyses showed that the fluorescein conjunctiva staining score was significantly correlated with the changes of dry eye-related symptom score at 12 weeks (P value = 0.017) and dry eye-related symptom score was significantly correlated with independent variables for the changes of FOS at 12 weeks (P value = 0.0097).

Conclusions

Two percent rebamipide ophthalmic suspension was an effective therapy for dry eye patients. Moreover the fluorescein conjunctiva staining score and dry eye-related symptom score might be good relevant factors for favorable effects of rebamipide.
Appendix
Available only for authorised users
Literature
1.
Miljanovic’ B, Dana R, Sullivan DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409–15.CrossRef
2.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5:75–92.
3.
Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318–26.CrossRefPubMed
4.
Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009;127:763–8.CrossRefPubMedPubMedCentral
5.
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5:93–107.
6.
Uchino M, Nishiwaki Y, Michikawa T, Shirakawa K, Kuwahara E, Yamada M, et al. Prevalence and risk factors of dry eye disease in Japan: Koumi study. Ophthalmology. 2011;118:2361–7.CrossRefPubMed
7.
Lemp MA. Tear film: new concepts and implications for the management of the dry eye. Trans New Orleans Acad Ophthalmol. 1987;35:53–64.PubMed
8.
Danjo Y, Watanabe H, Tisdale AS, George M, Tsumura T, Abelson MB, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci. 1998;39:2602–9.PubMed
9.
Shimazaki J. Definition and Diagnosis of Dry Eye 2006. J Eye. 2007;24:181–4.
10.
Kanaya Y, Hori Y, Muramatsu R, Deguchi Y, Shiba T, Maeno T. Comparison of Tear Meniscus Height after Different Methods of Fluorescein Staining. J Eye. 2013;30:1750–3.
11.
12.
Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.CrossRefPubMed
13.
Hikichi T, Yoshida A, Fukui Y, Hamano T, Ri M, Araki K, et al. A multicenter study on definite and probable dry eyes. Jpn J Clin Ophthalmol. 1994;48:1621–5.
14.
Myrtveit I, Stensrud E, Olsson UH. Analyzing data sets with missing data: an empirical evaluation of imputation methods and likelihood-based methods. IEEE Trans Soft Eng. 2001;27:999–1013.CrossRef
15.
Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N. Rebamipide Ophthalmic Suspension Phase II Study Group. Ophthalmology. 2012;119:2471–8.CrossRefPubMed
16.
Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N. Rebamipide Ophthalmic Suspension Phase 3 Study Group. Ophthalmology. 2013;120:1158–65.CrossRefPubMed
17.
Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N. Rebamipide Ophthalmic Suspension Long-term Study Group. A Multicenter, Open-Label, 52-Week Study of 2% Rebamipide (OPC-12759) Ophthalmic Suspension in Patients with Dry Eye. Am J Ophthalmol. 2014;157:576–83.CrossRefPubMed
18.
Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32:1219–23.CrossRefPubMed
19.
Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. 2002;43:1004–11.
20.
Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 2001;22:8–18.CrossRefPubMed
21.
Rios JD, Shatos M, Urashima H, Tran H, Dartt DA. OPC-12759 increases proliferation of cultured rat conjunctival goblet cells. Cornea. 2006;25:573–81.CrossRefPubMed
22.
Itoh S, Itoh K, Shinohara H. Regulation of Human Corneal Epithelial Mucins by Rebamipide. Curr Eye Res. 2013;39:133–41.CrossRefPubMed
23.
Zhang J, Yan X, Li H. Analysis of the correlations of mucins, inflammatory markers, and clinical tests in dry eye. Cornea. 2013;32:928–32.CrossRefPubMed
24.
Ueta M, Sotozono C, Yokoi N, Kinoshita S. Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells. J Ocul Pharmacol Ther. 2013;29:688–93.CrossRefPubMed
25.
Fujita M, Igarashi T, Kurai T, Sakane M, Yoshino S, Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. 2005;140:808–13.CrossRefPubMed
26.
Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, Kim TI, et al. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol. 2013;156:247–53.CrossRefPubMed
Metadata
Title
Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye
Authors
Kaori Ueda
Wataru Matsumiya
Keiko Otsuka
Yoshifumi Maeda
Takayuki Nagai
Makoto Nakamura
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2015
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-015-0040-0

Other articles of this Issue 1/2015

BMC Ophthalmology 1/2015 Go to the issue

Case report

Metastatic endophthalmitis combined with subretinal abscess in a patient with diabetes mellitus—a case report

Research article

Association between retinal vein occlusion, axial length and vitreous chamber depth measured by optical low coherence reflectometry

Research article

A comparative study of glaucoma referrals in Southeast Scotland: effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines

Research article

Comparison of resident and glaucoma faculty practice patterns in the care of open-angle glaucoma

Research article

Inferior retinotomy and silicone oil tamponade for recurrent inferior retinal detachment and grade C PVR in eyes previously treated with pars plana vitrectomy or scleral buckle

Research article

Evaluation of real-world mobility in age-related macular degeneration